We are managed under the umbrella of Merck KGaA, Darmstadt, Germany, a Corporation with general partners (Kommanditgesellschaft auf Aktien - KGaA). At least one partner has unlimited liability for the company’s creditors (general partner). The others (shareholders) hold an interest in the share capital without any personal liability for the company’s debts. It is therefore a hybrid of an Aktiengesellschaft (German stock corporation) and a Kommanditgesellschaft with a focus on German stock corporation law.
These are the differences between a German corporation with general partners and a German stock corporation:
Numerous resolutions made by the Annual General Meeting require the approval of the general partners
Shareholders hold around 30% of the total capital of Merck KGaA, Darmstadt, Germany, and the family owns an interest of around 70% via E. Merck KG, Darmstadt, Germany, the general partner.
Capital structure and corporate bodies of Merck KGaA, Darmstadt, Germany
Publication of Merck KGaA, Darmstadt, Germany.
In the USA and Canada the subsidiaries of Merck KGaA, Darmstadt, Germany operate as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Performance Materials. To reflect such fact and to avoid any misconception of the reader of the publication certain logos, terms and business descriptions of the publication have been substituted or additional descriptions have been added. Publications on this homepage, therefore, slightly deviate from the otherwise identical version of the publications provided outside the United States and Canada.
It takes just four genes to turn a differentiated cell, such as a skin cell, back into a stem cell that is available for new duties. With Simplicon, we are providing a new process for creating these cells.